Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CORTICOSTEROID FORMULATION
Document Type and Number:
WIPO Patent Application WO/2000/054780
Kind Code:
A2
Abstract:
A unit dose formulation comprising 0.25 to 2 mg of a corticosteroid. This small dose can be used to treat rheumatoid arthritis, especially if adapted to release at least 90 % by weight of the corticosteroid, 2 to 8 hours after administration.

More Like This:
JP4771565Sustained release formulation
WO/1995/003789CONTROLLED RELEASE OF PHARMACEUTICALLY ACTIVE SUBSTANCES FROM COACERVATE MICROCAPSULES
WO/1989/008448ENTERIC COATED SPHEROIDAL GRANULES
Inventors:
BARDSLEY HAZEL JUDITH (GB)
Application Number:
PCT/GB2000/000924
Publication Date:
September 21, 2000
Filing Date:
March 14, 2000
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ARAKIS LTD (GB)
BARDSLEY HAZEL JUDITH (GB)
International Classes:
A61K9/52; A61K9/28; A61K9/50; A61K31/57; A61K31/58; A61P1/04; A61P5/44; A61P11/06; A61P17/04; A61P19/02; A61P29/00; C07J9/00; C07J71/00; (IPC1-7): A61K31/57; A61K9/28; A61K9/50; A61P5/44; A61P19/02
Domestic Patent References:
WO1995008323A11995-03-30
Foreign References:
US5792476A1998-08-11
Attorney, Agent or Firm:
GILL JENNINGS & EVERY (Broadgate House 7 Eldon Street London EC2M 7LH, GB)
Download PDF:
View/Download PDF      PDF Help
Claims:
CLAIMS
1. A unit dose formulation comprising 0.25 to 2 mg of a corticosteroid.
2. A formulation according to claim 1, which comprises 0.5 to 2 mg of the corticosteroid.
3. A formulation according to claim 2, which comprises 1 to 1.25 mg of the corticosteroid.
4. A formulation according to any preceding claim, adapted to release at least 90% by weight of the corticosteroid, 2 to 8 hours after administration.
5. A formulation according to any preceding claim, wherein the corticosteroid is a glucocorticoid.
6. A formulation according to any preceding claim, wherein the corticosteroid is selected from prednisone, budesonide, methylprednisolone, prednisolone and deflazacort.
7. A formulation according to claim 6, wherein the corticosteroid is prednisolone.
8. Use of 0.25 to 2 mg of a corticosteroid for the manufacture of a controlledrelease unit dosage formulation, for use in the treatment of rheumatoid arthritis.
9. Use according to claim 8, wherein the formulation comprises 0.5 to 2 mg of the corticosteroid.
10. Use according to claim 9, wherein the formulation comprises 1 to 1.25 mg of the corticosteroid.
11. Use according to any of claims 8 to 10, wherein the formulation is adapted to release at least 90% by weight of the corticosteroid, 2 to 8 hours after administration.
12. Use according to any of claims 8 to 11, wherein the corticosteroid is a glucocorticoid.
13. Use according to any of claims 8 to 12, wherein the corticosteroid is selected from prednisone, budesonide, methylprednisolone, prednisolone and deflazacort.
14. Use according to claim 13, wherein the corticosteroid is prednisolone.
Description:
INTERNATIONALSEARCHREPORT Inter,malApplicatlon No infortnatlon on patent famlly members PCT/GB 00/00924 PatentdocumentPublicationPatentfamily Publication citedinsearchreportdatemember(s)date WO9508323A30-03-1995DE4332394A30-03-1995 AT173161T15-11-1998 CA2171852A30-03-1995 DE59407288D17-12-1998 EP0720473A10-07-1996 ES2124422T01-02-1999 JP9502972T25-03-1997 US5932249A03-08-1999 US5792476 A 11-08-1998 NONE



 
Previous Patent: OCULAR THERAPY IN KERATOCONJUCTIVITIS SICCA USING TOPICALLY APPLIED ANDROGENS OR TGF-$g(b)

Next Patent: TREATMENT OF ASTHMA